Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Off-label compounded bevacizumab
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Off-label compounded bevacizumab

4 evidence topics · 3 sources

Origin of off-label use

“ophthalmologists began treating neovascular AMD with off-label use of bevacizumab (Avastin, Genentech), since the drug had a target specificity similar to that of ranibizumab and was available at low cost.” (opens the source at this quote in a new tab)

Comparative efficacy versus ranibizumab (CATT trial)

“Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively.” (opens the source at this quote in a new tab)
“At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule.” (opens the source at this quote in a new tab)

Repackaging and contamination risk

“During March 6–8, 2013, four patients with age-related macular degeneration received a diagnosis of acute endophthalmitis” (opens the source at this quote in a new tab)
“Investigation of pharmacy A revealed multiple areas in which practices did not conform to United States Pharmacopeial Convention Chapter 797 standards for compounding sterile preparations or to recommended best practices for repackaging bevacizumab; these deficiencies might have contributed to bevacizumab contamination” (opens the source at this quote in a new tab)

Clinical decision-making around bevacizumab non-response

“For wet AMD patients who have a suboptimal response to Avastin (bevacizumab, Genentech) treatment, 88.4 percent of the physicians say they'll switch to Eylea (aflibercept, Regeneron). A smaller percentage, 11.1, say they'll switch to Lucentis.” (opens the source at this quote in a new tab)